Initial Testing (Stage 1) of Temozolomide by the Pediatric Preclinical Testing Program

BACKGROUND: The DNA methylating agent temozolomide was developed primarily for treatment of glioblastoma. However, preclinical data have suggested a broader application for treatment of childhood cancer. Temozolomide was tested against the PPTP solid tumor and ALL models. PROCEDURES: Temozolomide wa...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pediatr Blood Cancer
Auteurs principaux: Keir, Stephen T., Maris, John M., Reynolds, C. Patrick, Kang, Min H., Kolb, E. Anders, Gorlick, Richard, Lock, Richard, Carol, Hernan, Morton, Christopher L., Wu, Jianrong, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4244112/
https://ncbi.nlm.nih.gov/pubmed/23335050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24368
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires